Personal Statement
Dr. Cadigan is an Assistant Professor and licensed psychologist in the Department of Psychiatry and Behavioral Sciences. She received her Ph.D. from the University of Missouri in 2016 and then completed clinical psychology internship and fellowship at the University of Washington Medical Center.
Her program of research focuses on adolescent and young adult health and wellbeing, with an emphasis on the etiology, prevention, and intervention of substance misuse and co-occurring mental health concerns. This work aims to develop, test, and disseminate innovative prevention and intervention programs to reduce substance misuse and improve mental health among adolescents and young adults. This work has included developing and testing programs for young adults who use substances to cope with negative affect and loneliness. Her work has also examined etiological factors related to co-occurring mental health and substance use, including the effects of loneliness, depression, coping motives, social support, solitary substance use, and factors associated with improving access to mental health care.
Clinically, she works with adolescents presenting with depression and suicidality at Seattle Children’s Hospital in the Behavioral Health Crisis Care Clinic and in the Mood and Anxiety Program.
- Recent Grants:
- Development of a behavioral economic intervention with personalized resource allocation feedback to reduce young adult alcohol misuse (PI: Cadigan, NIH/NIAAA1R34AA029478)
- Development of an interactive, we-based drinking to cope intervention and tools to assess coping skill utilization (PI: Cadigan, NIH/NIAAA R34AA028074)
Personal Statement
The transition to adulthood is the developmental period when alcohol use, marijuana use, and their associated consequences reach their lifetime peak. My scholarly interests focus on the etiology and prevention of substance use behaviors and consequences during adolescence and young/early adulthood. I have developed a highly successful portfolio of work bridging developmental, social, and motivational theory with applied prevention and intervention techniques to strategically address high-risk behaviors during the transition to adulthood.
My research addresses important questions regarding how recent marijuana legislation in Washington State impacts young adult marijuana use and consequences; what motivates young adults to engage in alcohol and marijuana use; how alcohol expectancies, alcohol use and consequences are linked in a natural feed-forward process that maintains high-risk behaviors; how developmental transitions and event timing influence use; and what are efficacious prevention and intervention strategies and for whom and under what conditions are these most effective.
Personal Statement
I have been a member of the department faculty since 1995. My research and clinical interests include 1) prevention and treatment of alcohol and drug problems among adolescents and young adults (with a particular focus on college drinking prevention), 2) prediction of initiation of drinking and trajectories of alcohol and substance use during emerging adulthood, 3) co-morbidity of substance use with depression, suicide, trauma, PTSD, disordered eating, and gambling problems, 4) evaluation of housing and treatment programs for chronically homeless and incarcerated individuals and 5) dissemination of evidence-based prevention and treatment approaches into clinical, school, and work-site settings. I have published more than 100 articles and book chapters on these topics.
Personal Statement
My primary interest is on determining how behavioral technologies can be used to improve alcohol and drug abuse outcomes for those suffering from addiction health disparities. Behavioral technologies are non-talk therapy approaches to addiction treatment, such as motivational incentives where we provide rewards for people who abstain from or reduce their drinking. This low-cost, strength based approach to addiction can be implemented in low-resources settings by non clinicians. In fact, our group is investigating how smartphones might be used to implement this treatment, allowing us to reach the millions of individuals suffering from alcohol problems worldwide.
My second research interest in evaluating the accuracy of alcohol biomarkers in addiction treatment settings. These include alcohol urine tests, such as ethyl glucuronide (EtG) and mobile phone linked Bluetooth breathalyzers. These tools allow us to accurately assess the success of alcohol treatments, as well as provide valuable research tools.
Importantly all of my research studies are conducted in collaboration with two communities that suffer disproportionately high rates of alcohol and drug misuse, 1) adults with severe mental illnesses, like schizophrenia and bipolar disorder and 2) American Indians and Alaska Natives. My research team and I work closely with community partners who are providing addiction treatment to these populations with the goal of reducing the burden of alcohol and drug use in these communities.
Personal Statement
Jane Luterek, PhD is a psychologist in the PTSD Outpatient Clinic and the Addictions Treatment Center focused primarily on serving women Veterans at the VA Puget Sound Healthcare System, Seattle Division. She is a Clinical Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington and is licensed in the State of Washington. Dr. Luterek’s research has focused on understanding the psychological sequelae of trauma and mechanisms of change in therapy associated with Alcohol Dependence and PTSD. She has advanced clinical training in the treatment of Veterans with trauma related psychological sequelae (e.g. substance use disorders, PTSD, mood disorders, borderline personality disorder) and draws from a contextual behavioral theoretical background. Dr. Luterek has expertise in Acceptance and Commitment Therapy, Prolonged Exposure, Dialectical Behavior Therapy, and Motivational Interviewing, which heavily inform her clinical practices.
Personal Statement
My area of expertise is addiction psychiatry.
Personal Statement
I have pursued a career at the intersection of mental health and primary care, training in both family medicine and addiction psychiatry. I currently practice in various integrated care settings as a consulting psychiatrist and in the outpatient adult psychiatry clinic. I am the co-medical director for the University of Washington Psychiatry and Addiction Case Conference (UW PACC), a weekly online learning collaborative to help community providers across the state improve their psychiatric and addiction clinical skills. My area of interest is focused on improving addiction and psychiatric treatment to primary care settings. I also spend a significant amount of time training both family medicine and psychiatry trainees and fellows on integrated treatments for substance use disorders.
Personal Statement
My clinical service and research focuses on the interaction of mental and physical illness, especially in patients with chronic pain. Much of my research in recent decades has focused on the risks of treating chronic pain with opioids. I have developed educational programs and outcome tracking tools to assist with opioid treatment of chronic pain. I have published a book about patient empowerment in chronic disease care, The Patient as Agent of Health and Health Care (Oxford, 2017). I have another book written with Jane Ballantyne forthcoming, The Right to Pain Relief and other deep roots of the opioid epidemic (Oxford, 2022).
Personal Statement
My lab’s focus is reward processing, how it differs under behavior phenotypes that are more vulnerable or resilient to mental illness and how it is changed by psychiatric pathology. Our primary focus is dopamine transmission and the circuits in which is participates.
We developed tools that allow us to track dopamine with sub-second resolution in animals over the course of months (Clark et al, Nat Methods, 2010). This approach allows us to study trajectories of precise neurochemical encoding of behaviors over the course of the development of symptomology and subsequent treatment in animal models of disease. We also have adapted this technology for intraoperative recording in humans (Kishida et al, PLoS One, 2011).
Our research highlights include contributions in the area of dopamine’s role in learning (Flagel et al, Nature, 2012), decision making (Gan et al, Nat Neurosci, 2010) and goal navigation (Howe et al, Nature, 2013). We have gleaned information on how stress impacts appetitive motivation (Wanat et al, Nat Neurosci, 2013), how adolescent alcohol use produces enhanced risk taking later in life (Clark et al, PLoS One, 2012), and identified biological mechanisms for the motivational shift in stress-induced depressive disorders (Lemos et al, Nature, 2012) and the switch to excessive drug intake in substance abuse (Willuhn et al, Nat Neurosci, 2014).
These approaches have attracted a large number of collaborations, including National Academy members Akil, Palmiter, Graybiel and Kandel.
